Bayer Enters the First-Line HER2 Lung Cancer Arena With a Tolerability Handicap
The FDA has granted accelerated approval to Bayer's Hyrnuo as a frontline therapy in HER2-mutant lung cancer, matching rival zongertinib's response rates while carrying twice-daily meal requirements and steeper gastrointestinal toxicity.
The Food and Drug Administration on September 9, 2026 expanded accelerated approval of Bayer's oral tyrosine kinase inhibitor Hyrnuo (sevabertinib) to previously untreated adults with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 (ERBB2) tyrosine kinase domain activating mutations, detected by an FDA-authorized test such as Life Technologies' Oncomine Dx Target Test. The label now covers treatment-naive disease after an initial accelerated nod on November 19, 2025 in previously treated patients. The frontline objective response rate looks competitive. The terms of entry do not.
HER2 mutations appear in 2% to 4% of NSCLC, often in younger never-smokers, with brain metastases in 20% to 30% of cases. For years the only targeted option after chemotherapy was intravenous trastuzumab deruxtecan (Enhertu), which delivered a 49% response rate in DESTINY-Lung02 but carries a boxed warning for interstitial lung disease that proved fatal in about 2% of patients. Two oral TKIs have now entered that sequence. A 75% response rate will not, by itself, displace a first-mover with cleaner guts and simpler dosing.
A statistical tie on response, not on the clinic floor
In SOHO-01 (trial NCT05099172), an open-label, multicenter Phase 1/2 study of sevabertinib at 20 mg twice daily, the treatment-naive Cohort F (N=69) posted a confirmed objective response rate of 75%, including a 6% complete response rate and a 70% partial response rate. Duration of response was durable enough for accelerated approval: 73% of responders held the response for at least six months, and 38% held it for at least 12 months. Those figures were published as the registrational cut.
Boehringer Ingelheim's Hernexeos (zongertinib) was cleared as an initial first-line option on February 26, 2026, after an August 2025 approval in previously treated patients. In Beamion LUNG-1 Cohort 2 (N=74, 120 mg once daily), confirmed ORR was 76% (95% CI 65 to 84), with an 11% complete response rate and a 65% partial response rate. Median duration of response was 15.2 months. Median progression-free survival was 14.4 months. The NEJM paper that reported those data also locked in a once-daily, with-or-without-food schedule (120 mg for patients under 90 kg). Hyrnuo is 20 mg twice daily with food, and high-fat meals are to be avoided. Response rates of 75% and 76% will not differentiate a launch. Dosing might.
EGFR sparing shows up in the diarrhea table
Zongertinib is an irreversible covalent kinase inhibitor engineered to hit mutant HER2 while sparing wild-type EGFR. Sevabertinib is less selective on that axis, and the safety tables show it. Treatment-related diarrhea hit 86.4% to 91% of patients on sevabertinib across SOHO-01 cohorts. Grade 3 diarrhea reached 25% in pretreated Cohort D and 5.5% to 14% in frontline cuts. Dose reductions occurred in 31.8% of patients. Discontinuation for drug-related adverse events stayed low, at 3% to 6.8%. Other common events included rash, paronychia, increased AST and ALT, and nausea. Interstitial lung disease or pneumonitis appeared in 0.7% of the pooled safety population, thinner than Enhertu's boxed warning.
On zongertinib, overall diarrhea was 55% and Grade 3 treatment-related diarrhea was 3%. Grade 3 or higher treatment-related adverse events were 19%. Dose reductions occurred in 16% of patients, with discontinuation in 6% to 9%. A 31.8% dose-reduction rate versus 16% is clinic-floor friction that shapes real-world persistence even when discontinuation looks similar.
Brain mets and the confirmatory lease
With brain metastases in 20% to 30% of HER2-mutant NSCLC, intracranial activity is a first-line selection criterion. Beamion LUNG-1's exploratory Cohort 4 enrolled 30 patients with active brain metastases and delivered a 47% intracranial objective response rate (57% in radiotherapy-naive patients) and a median intracranial PFS of 8.2 months. SOHO-01 has not put a comparable prospective intracranial package in front of the FDA for patients with active brain mets.
Post-ADC sequencing still favors an oral TKI on the shelf. In SOHO-01 Cohort E, sevabertinib produced a 38% ORR and a median PFS of 5.5 months after HER2 antibody-drug conjugate progression. Resistance data at WCLC 2026 (Xiuning Le and colleagues, abstract MO12.04) found secondary HER2 T862A mutations in 16.4% of progressing patients, without emergent C805S.
Accelerated approval is a lease. SOHO-02 (NCT06452277) pits sevabertinib against pembrolizumab plus platinum-pemetrexed in untreated HER2 TKD-mutant NSCLC. Beamion LUNG-2 (NCT06151574) is running the same confirmatory race for zongertinib. Until those readouts, both labels rest on single-arm ORR. Bayer's problem is that the lease started seven months late, on a twice-daily meal-timed schedule, with diarrhea rates that force more dose cuts and with no prospective active-brain-met signal to match 47%.
Matching a 76% response rate gets Hyrnuo onto the first-line menu. It does not erase a first-mover purpose-built to spare EGFR, dosed once daily, and already documenting intracranial responses. The remaining fight is whether Bayer can convert a statistical tie on ORR into share when the clinic already has a cleaner, simpler alternative.